| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | MPPH; PKBG; MPPH2; PRKBG; STK-2; PKB-GAMMA; RAC-gamma; RAC-PK-gamma |
| Entrez GeneID | 10000 |
| WB Predicted band size | Calculated MW: 56 kDa; Observed MW: 56 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human AKT1/2/3 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于AKT抗体的3-4篇文献示例(信息基于公开研究总结，非真实引用)：
---
1. **文献名称**：*"AKT/PKB Signaling: Navigating the Network"*
**作者**：Brazil, D.P. et al.
**摘要**：该综述系统总结了AKT(蛋白激酶B)的分子结构、激活机制及其在细胞存活、增殖和代谢中的核心作用。文中强调了针对不同AKT亚型(AKT1/2/3)和磷酸化位点(如Ser473、Thr308)的特异性抗体的开发与应用，为研究AKT信号通路的实验设计提供了抗体选择指南。
2. **文献名称**：*"The PI3K-AKT Network at the Interface of Oncogenic Signalling and Cancer Metabolism"*
**作者**：Manning, B.D. & Cantley, L.C.
**摘要**：研究探讨了AKT在癌症代谢重编程中的作用，重点分析了AKT抗体在检测肿瘤组织中AKT活性(如磷酸化状态)的应用，并比较了不同商业抗体在免疫印迹(Western blot)和免疫组化(IHC)中的特异性与灵敏度。
3. **文献名称**：*"Tissue-Specific Roles of AKT Isoforms in Metabolism and Disease"*
**作者**：Hers, I. et al.
**摘要**：通过基因敲除和抗体介导的蛋白检测，该研究揭示了AKT1、AKT2和AKT3在不同组织代谢中的独特功能。作者强调使用亚型特异性抗体(如AKT2单克隆抗体)对精准解析AKT功能的重要性，并验证了多种抗体在临床前模型中的可靠性。
4. **文献名称**：*"AKT Inhibitors in Cancer Therapy: From Bench to Bedside"*
**作者**：Santi, S.A. & Lee, H.
**摘要**：文章评估了AKT靶向药物的临床效果，并利用AKT磷酸化抗体(如p-AKT Ser473)监测药物治疗后肿瘤细胞信号通路的抑制效果。研究指出抗体选择需结合实验条件(如样本类型、检测方法)以确保结果准确性。
---
以上内容为示例，实际文献需通过学术数据库(如PubMed)检索确认。如需具体文献，建议结合关键词“AKT antibody validation”、“phospho-AKT detection”进一步筛选。
**Background of AKT Antibodies**
AKT (protein kinase B) is a serine/threonine kinase central to the PI3K/AKT/mTOR signaling pathway, which regulates critical cellular processes including growth, survival, metabolism, and proliferation. Dysregulation of AKT is implicated in various diseases, particularly cancer, diabetes, and neurodegenerative disorders. Three isoforms exist—AKT1. AKT2. and AKT3—encoded by distinct genes, each with tissue-specific expression and unique functional roles. AKT activation occurs via phosphorylation: PDK1 phosphorylates Thr308 (AKT1), and mTORC2 phosphorylates Ser473. enabling full kinase activity.
AKT antibodies are essential tools for detecting and studying AKT expression, activation, and localization in research and diagnostics. They are designed to target specific epitopes, such as total AKT (pan-AKT), individual isoforms, or phosphorylation sites (e.g., p-AKT Thr308/Ser473), enabling precise analysis of AKT signaling dynamics. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry.
In cancer research, AKT antibodies help assess pathway hyperactivation, correlate with tumor progression, and evaluate therapeutic responses to PI3K/AKT inhibitors. Isoform-specific antibodies aid in distinguishing their roles, such as AKT1 in tumor growth versus AKT2 in insulin signaling. Validation of antibody specificity remains critical, as cross-reactivity between isoforms or phosphorylation states can lead to misinterpretation. Overall, AKT antibodies are pivotal in elucidating disease mechanisms and advancing targeted therapies.
×
